Skip to main content
. Author manuscript; available in PMC: 2012 Jan 15.
Published in final edited form as: Am J Health Syst Pharm. 2011 Jan 15;68(2):143–150. doi: 10.2146/ajhp100113

Table 1.

Pharmacogenetic tests selected for inclusion in Clinical Pharmacogenetics Service and key affected drugs.

Gene Key Affected Drugs on
Institution’s Formulary		 Effect of variant allele FDA-approved genetic
information in product
labeling?
Thiopurine methyltransferase (TPMT) 30–32 6-mercaptopurine
Thioguanine
Azathioprine		 Severe, sometimes fatal,
hematological toxicity24,33–35 		Yes
Cytochrome P450 2D6 (CYP2D6)36,37 Codeine CYP2D6 poor metabolizers
and receive no analgesic
effect from codeine;38
ultrarapid metabolizers of
CYP2D6 are at very high risk
of toxicity to codeine39 		Yes
Uridine glucuronosyltransferase 1A1
(UGT1A1)		 Irinotecan Increased potential for
hematological or
gastrointestinal toxicity40 		Yes